May 01, 2012
Bernstein Liebhard LLP is investigating whether the Board of Directors of Gen-Probe Incorporated (“Gen-Probe” or the “Company”) (NASDAQ: GPRO) breached its fiduciary duty to its shareholders in agreeing to sell Gen-Probe to Hologic, Inc. (NASDAQ: HOLX).
Under the terms of the agreement, Gen-Probe shareholders will receive $82.75 in cash for each share they own. The investigation is focused on the potential unfairness of the price to Gen-Probe shareholders and the process by which the Gen-Probe Board of Directors considered and approved the transaction.
Bernstein Liebhard has pursued hundreds of securities, consumer and shareholder rights cases and recovered over $3 billion for its clients. It has been named to The National Law Journal’s “Plaintiffs’ Hot List” in each of the last nine years.